a place fir glp.1 and eating disprders GLP-1 access problem for people with disorders Eating Disorder Treatment Centers -

There is also a theoretical concern about additive hypoglycemic effects, particularly in patients taking other diabetes medications or insulin

These changes markedly reduce its affinity for the insulin-like growth factor-binding proteins (IGFBPs) while retaining agonist activity at the IGF-1 receptor, characteristics that make it a useful reference ligand in growth-factor biology

Journal of Perinatal Medicine

[11] [12] Currently available GLP-1 receptor agonists in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GLP-1/GIP receptor agonist

Intimately familiar with the amino acid structure of glucagon, Mojsov had a hunch that the active part of GLP-1 might in fact be located in a small stretch of the peptide

Pandya, C